systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»systhiper-393Research ArticleОБЗОРЫЕще раз о клинической эффективности и безопасности сартановOnce again about the clinical efficacy and safety of sartansМининаЕ. С.MininaYe. S.noemail@neicon.ruХаджиеваБ. Р.KhadzhievaB. R.noemail@neicon.ruФГБУ Поликлиника №3 Управления делами Президента РФ, МоскваРоссияГБОУ ВПО Первый московский государственный медицинский университет им. И.М.Сеченова Минздрава РоссииРоссия2014231220221148486Copyright © Минина Е.С., Хаджиева Б.Р., 20222022Минина Е.С., Хаджиева Б.Р.Minina Y.S., Khadzhieva B.R.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/393

Сартаны в настоящее время - наиболее безопасный и эффективный класс гипотензивных препаратов. У пациентов, страдающих артериальной гипертензией (АГ), наибольшая приверженность лечению наблюдается именно при назначении сартанов. Их эффективность определяет сила связи с рецептором ангиотензина II 1-го типа. Наиболее сильна связь с рецептором у кандесартана и азилсартана. При этом кандесартан по сравнению с азилсартаном имеет широкие показания. У азилсартана показанием служит АГ. Данные сартаны освещены с точки зрения эффективности и безопасности.

Sartans are safety and effective class of anti-hypertensives nowadays. Sartans are the most effective inpatients suffering from arterial hypertension. Their efficiency is determined by the association of Angiotensin II type 1 receptor. Candesartan and azilsartan are themost powerful and approved angiotensin receptor blockers. Candesartan in comparison with azilsartan has wide proposed spectrum of clinical use. Azilsartan is indicated for the treatment of arterial hypertension. In terms of efficiency and safety we showed these sartans.

сартаныкандесартаназилсартанартериальная гипертензияхроническая сердечная недостаточностьsartanscandesartanazilsartanarterial hypertensionchronic heart failureReferencesConlin P.R, Gerth W.C, Fox J et al. Four - year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23 (12): 1999-2010.Conlin P.R, Gerth W.C, Fox J et al. Four - year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 2001; 23 (12): 1999-2010.Erkens J.A, Panneman M.M, Klungel O.H et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14 (11): 795-803.Erkens J.A, Panneman M.M, Klungel O.H et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14 (11): 795-803.Van Liefde I, Vauquelin G. Sartan AT1-receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237-43.Van Liefde I, Vauquelin G. Sartan AT1-receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302 (2): 237-43.Ojima M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.Ojima M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336 (3): 801-8.Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; (11 Suppl. 2): s49-53.Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; (11 Suppl. 2): s49-53.Lindholm L.H, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21 (8): 1563-74.Lindholm L.H, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21 (8): 1563-74.Asmar R, Nisse-Durgeat S. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study. Vasc Health Risk Manag 2006; 2 (3): 317-23.Asmar R, Nisse-Durgeat S. A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study. Vasc Health Risk Manag 2006; 2 (3): 317-23.Granger C.B, Mc Murray J.J, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM. Alternative Trial Lancet 2003; 362: 772-6.Granger C.B, Mc Murray J.J, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin converting enzyme inhibitors: the CHARM. Alternative Trial Lancet 2003; 362: 772-6.Мареев В.Ю., Агеев Ф.Т. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (2-й пересмотр). Сердечная недостаточность. 2006; 8 (2).Мареев В.Ю., Агеев Ф.Т. и др. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (2-й пересмотр). Сердечная недостаточность. 2006; 8 (2).Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double - blind intervention trial. J Hypertens 2003; 21: 875-86.Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double - blind intervention trial. J Hypertens 2003; 21: 875-86.Rakugi H et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double - blind clinical study. Hypertens Res 2012; 35 (5): 552-8.Rakugi H et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double - blind clinical study. Hypertens Res 2012; 35 (5): 552-8.Инструкция по медицинскому применению препарата Эдарби®. URL: http://grls.rosminzdrav.ru/Grls_View.aspx?idReg= 146017&isOld=0&tИнструкция по медицинскому применению препарата Эдарби®. URL: http://grls.rosminzdrav.ru/Grls_View.aspx?idReg= 146017&isOld=0&tИнструкция по медицинскому применению препарата АтакандR. URL: http://grls.rosminzdrav.ru/ImgInstr.aspx?folder= ScanVavilova&Filepath=/Ne_trebuet_vnesenia/Net_ND_IZM/439736/ IP_IZM&idReg=106933&isOld=0&fileType=jpg&pfolder=2Инструкция по медицинскому применению препарата АтакандR. URL: http://grls.rosminzdrav.ru/ImgInstr.aspx?folder= ScanVavilova&Filepath=/Ne_trebuet_vnesenia/Net_ND_IZM/439736/ IP_IZM&idReg=106933&isOld=0&fileType=jpg&pfolder=2Reif M et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998; 82: 961-5.Reif M et al. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1998; 82: 961-5.Bonner G, Bakris G, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479-86.Bonner G, Bakris G, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin - converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479-86.Sica D et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. Clin Hypertens (Greenwich) 2011; 13 (7): 467-72.Sica D et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. Clin Hypertens (Greenwich) 2011; 13 (7): 467-72.

The authors declare that there are no conflicts of interest present.